Zolex Therapeutics is developing two novel classes of small molecular weight antibiotics to treat Staphylococcus aureus (SA), including the Methicillin-resistant SA (MRSA) strains (classified by the WHO in 2017 as "high priority" pathogens).

 

With the O'Neill Commission forecasting an increase in the annual “superbug” death-toll to as many as 10 million people by 2050, there is an urgent need to develop more effective antibacterial entities to thwart bacterial resistance. 

 

Zolex’s therapeutic pipelines for oral and injectable administration will provide a much-needed boost to today’s limited number of approved treatments for MRSA.

 

Both of the company’s chemical series were in-licensed from the University of Notre Dame, South Bend, Indiana.